查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1193239

高度活躍的 API 市場：按產品類型、應用、合成類型分類：2021-2031 年全球機遇分析和行業預測

High Potency APIs Market By Product Type, By Application, By Type of Synthesis : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 310 Pages | 商品交期: 2-3個工作天內

價格

全球高活性 API 市場預計 2021 年將達到 196.9365 億美元，2031 年將達到 413.7334 億美元，2022 年至 2031 年的複合年增長率為 7.7%。

高活性 API 是一種即使在非常低的劑量下也能引起生物反應的物質。 細胞毒劑和性激素（如雌激素）是 HPAPI 的常見例子，它們表現出高選擇性和低劑量反應。 此外，由於芬太尼、阿普唑侖、利培酮、布美他尼和比索普諾等低濃度誘導反應的高活性藥物的開發，包括 HPAPI 開發在內的原料藥開發是製藥行業增長最快的部分。被投放市場用於治療各種疾病。 此外，還有1000多種可用於治療癌症、糖尿病、青光眼等疾病的高活性小分子藥物正在研發中。

根據國家青光眼研究，超過 300 萬美國人患有青光眼，其中 270 萬人年齡在 40 歲以上，並且患有最常見的開角型青光眼。 2020年全球約有8000萬人患有青光眼，預計到2040年這一數字將增至1.11億以上。 青光眼患者數量的增加，以及癌症和糖尿病等其他多基因疾病的全球流行，正在推動高度活躍的 API 市場的增長。

此外，該市場的主要參與者正在尋求在印度、中國和中東等新興國家/地區進行投資以擴大業務。 該地區不斷增長的人口、製造業所需的過剩原材料供應以及政府資金是推動該地區市場增長的一些因素。 此外，根據 NCBI 的數據，原發性閉角型青光眼 (PACG) 在亞洲人中比在歐洲人和非洲人中更常見，佔全球總數的 80% 以上，是高度活躍的 API 市場的主要市場參與者。投資機會的預測期。

目次

第 1 章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
  • COVID-19 影響分析
  • 專利情況

第 4 章高度活躍的 API 市場：按產品類型分類

  • 概覽
    • 市場規模和預測
  • 創新的高活性 API
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：國家分析
  • 通用高濃度 API
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 5 章高度活躍的 API 市場：按應用

  • 概覽
    • 市場規模和預測
  • 腫瘤科
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 荷爾蒙失調
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 青光眼
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 6 章高度活躍的 API 市場：按合成類型

  • 概覽
    • 市場規模和預測
  • 綜合
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 生物技術
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
    • 生物技術高度活躍的 API 市場：按類型分類
      • 商家市場規模趨勢和預測：按地區
      • 專屬市場規模和按地區預測

第 7 章高度活躍的 API 市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按產品類型
    • 北美市場規模和預測：按應用
    • 北美市場規模和預測：按合成類型
      • 北美生物技術高活性 API 市場：按類型分類
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機遇
    • 歐洲市場規模和預測：按產品類型
    • 歐洲市場規模和預測：按應用分類
    • 歐洲市場規模和預測：按合成類型
      • 歐洲生物技術高活性 API 市場：按類型分類
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲
  • 亞太地區
    • 主要趨勢和機遇
    • 亞太地區市場規模和按產品類型預測
    • 亞太地區的市場規模和預測：按應用分類
    • 亞太市場規模和預測：按合成類型
      • 亞太地區生物技術高活性 API 市場：按類型分類
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機遇
    • LAMEA 市場規模和預測：按產品類型
    • LAMEA 市場規模和預測：按應用分類
    • LAMEA 市場規模和預測：按合成類型
      • LAMEA 生物技術高活性 API 市場：按類型分類
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其餘部分

第 8 章公司情況

  • 介紹
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第 9 章公司簡介

  • AbbVie Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
Product Code: A31461

The global high potency APIs market was valued at $19,693.65 million in 2021, and is projected to reach $41,373.34 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.

High potency APIs are the substances that elicit a biological response even at very low doses. Cytotoxic substances and sex hormones like oestrogen are the common examples of HPAPIs which are highly selective in nature and show response at low doses. Moreover, the API development sector including the development of the HPAPIs, is the fastest expanding area of the pharmaceutical industry due to the development of the highly potent drugs such as fentanyl, alprazolam, risperidone, bumetanide, bisoprolol that evokes response at low concentrations and are into the market for the treatment of various ailments. In addition, more than 1,000 highly potent small molecules are under development that have their applications in the treatment of diseases like cancer, diabetes, glaucoma, and others.

According to the National Glaucoma Research, more than three million Americans have glaucoma, and 2.7 million of these patients are aged 40 and older and are affected by its most common form, open-angle glaucoma. Also, in 2020, about 80 million people have glaucoma globally, and this number is expected to increase to over 111 million by 2040. This rise in the number of the glaucoma patients, along with the prevalence of other multi-genetic disorders such as cancer, diabetes, and others around the globe, propel the growth of the high potency APIs market.

Furthermore, the key market players in the market are focusing on the emerging economies such as India, China and the Middle East Asia for investment and expansion of their business. The rise in the population in this region, along with prevalence of the excessive raw materials for the manufacturing and funding offered by the government are the factors driving the growth of the market in this region. In addition, NCBI states that the primary angle closure glaucoma (PACG) is higher in Asians than Europeans and Africans, with over 80% of the total cases globally, which highlights the investment opportunities for the key market players in the high potency APIs market during the forecast period.

In addition, there is an increase in the demand for oncology drugs due to the prevalence of the cancer cases around the globe. Also, advancements in HPAPI manufacturing technologies along with the rise in the number of contract manufacturing organization (CMOs) and contract development and manufacturing organization (CDMOs) are the factors driving the growth of the market. On the other hand, the patent expiry and launch of the generic versions of the highly potent APIs are projected to provide lucrative opportunity for the pharmaceutical companies to enhance product portfolio and expand their business.

However, the market is expected to be significantly constrained in the near future due to the high risk of cross-contamination and high development cost associated with the manufacturing process. The market is capital intensive and requires skilled technical human capital. This is projected to be a major barrier for new entrants entering the market.

The high potency APIs market is segmented on the basis of product type, application, type of synthesis and region. By product type, it is divided into innovative high-potency API and generic high-potency API. On the basis of application, the market is segmented into oncology, hormonal imbalance, glaucoma, and others. According to the type of synthesis, the market is segmented into synthetic and biotech. The biotech is further divided into merchant and captive. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in this report include Abbvie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. and others.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the high potency apis market analysis from 2021 to 2031 to identify the prevailing high potency apis market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the high potency apis market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global high potency apis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Application

  • Oncology
  • Hormonal Imbalance
  • Glaucoma
  • Others

By Type of Synthesis

  • Synthetic
  • Biotech
    • Type
    • Merchant
    • Captive

By Product Type

  • Innovative High-Potency API
  • Generic High-Potency API

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • AbbVie Inc.
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche
    • Novartis International AG
    • Pfizer, Inc.
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Patent Landscape

CHAPTER 4: HIGH POTENCY APIS MARKET, BY PRODUCT TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Innovative High-Potency API
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Generic High-Potency API
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country

CHAPTER 5: HIGH POTENCY APIS MARKET, BY APPLICATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Oncology
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Hormonal Imbalance
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Glaucoma
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
  • 5.5 Others
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country

CHAPTER 6: HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Synthetic
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Biotech
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
    • 6.3.4 Biotech High Potency APIs Market by Type
      • 6.3.4.1 Merchant Market size and forecast, by region
      • 6.3.4.2 Captive Market size and forecast, by region

CHAPTER 7: HIGH POTENCY APIS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Product Type
    • 7.2.3 North America Market size and forecast, by Application
    • 7.2.4 North America Market size and forecast, by Type of Synthesis
      • 7.2.4.1 North America Biotech High Potency APIs Market by Type
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Product Type
      • 7.2.5.1.2 Market size and forecast, by Application
      • 7.2.5.1.3 Market size and forecast, by Type of Synthesis
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Product Type
      • 7.2.5.2.2 Market size and forecast, by Application
      • 7.2.5.2.3 Market size and forecast, by Type of Synthesis
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Product Type
      • 7.2.5.3.2 Market size and forecast, by Application
      • 7.2.5.3.3 Market size and forecast, by Type of Synthesis
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Product Type
    • 7.3.3 Europe Market size and forecast, by Application
    • 7.3.4 Europe Market size and forecast, by Type of Synthesis
      • 7.3.4.1 Europe Biotech High Potency APIs Market by Type
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Product Type
      • 7.3.5.1.2 Market size and forecast, by Application
      • 7.3.5.1.3 Market size and forecast, by Type of Synthesis
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Product Type
      • 7.3.5.2.2 Market size and forecast, by Application
      • 7.3.5.2.3 Market size and forecast, by Type of Synthesis
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Product Type
      • 7.3.5.3.2 Market size and forecast, by Application
      • 7.3.5.3.3 Market size and forecast, by Type of Synthesis
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Product Type
      • 7.3.5.4.2 Market size and forecast, by Application
      • 7.3.5.4.3 Market size and forecast, by Type of Synthesis
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Product Type
      • 7.3.5.5.2 Market size and forecast, by Application
      • 7.3.5.5.3 Market size and forecast, by Type of Synthesis
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Product Type
      • 7.3.5.6.2 Market size and forecast, by Application
      • 7.3.5.6.3 Market size and forecast, by Type of Synthesis
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Product Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Application
    • 7.4.4 Asia-Pacific Market size and forecast, by Type of Synthesis
      • 7.4.4.1 Asia-Pacific Biotech High Potency APIs Market by Type
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Product Type
      • 7.4.5.1.2 Market size and forecast, by Application
      • 7.4.5.1.3 Market size and forecast, by Type of Synthesis
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Product Type
      • 7.4.5.2.2 Market size and forecast, by Application
      • 7.4.5.2.3 Market size and forecast, by Type of Synthesis
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Product Type
      • 7.4.5.3.2 Market size and forecast, by Application
      • 7.4.5.3.3 Market size and forecast, by Type of Synthesis
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Product Type
      • 7.4.5.4.2 Market size and forecast, by Application
      • 7.4.5.4.3 Market size and forecast, by Type of Synthesis
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Product Type
      • 7.4.5.5.2 Market size and forecast, by Application
      • 7.4.5.5.3 Market size and forecast, by Type of Synthesis
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Product Type
      • 7.4.5.6.2 Market size and forecast, by Application
      • 7.4.5.6.3 Market size and forecast, by Type of Synthesis
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Product Type
    • 7.5.3 LAMEA Market size and forecast, by Application
    • 7.5.4 LAMEA Market size and forecast, by Type of Synthesis
      • 7.5.4.1 LAMEA Biotech High Potency APIs Market by Type
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Product Type
      • 7.5.5.1.2 Market size and forecast, by Application
      • 7.5.5.1.3 Market size and forecast, by Type of Synthesis
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Product Type
      • 7.5.5.2.2 Market size and forecast, by Application
      • 7.5.5.2.3 Market size and forecast, by Type of Synthesis
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Product Type
      • 7.5.5.3.2 Market size and forecast, by Application
      • 7.5.5.3.3 Market size and forecast, by Type of Synthesis
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Product Type
      • 7.5.5.4.2 Market size and forecast, by Application
      • 7.5.5.4.3 Market size and forecast, by Type of Synthesis

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 AbbVie Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Bayer AG
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Boehringer Ingelheim International GmbH
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Bristol-Myers Squibb Company
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Eli Lilly and Company
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 F. Hoffmann-La Roche
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Novartis International AG
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Pfizer, Inc.
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Sanofi
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Teva Pharmaceutical Industries Ltd.
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 2. HIGH POTENCY APIS MARKET, FOR INNOVATIVE HIGH-POTENCY API, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. HIGH POTENCY APIS MARKET FOR INNOVATIVE HIGH-POTENCY API, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. HIGH POTENCY APIS MARKET, FOR GENERIC HIGH-POTENCY API, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. HIGH POTENCY APIS MARKET FOR GENERIC HIGH-POTENCY API, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. GLOBAL HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 7. HIGH POTENCY APIS MARKET, FOR ONCOLOGY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. HIGH POTENCY APIS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 9. HIGH POTENCY APIS MARKET, FOR HORMONAL IMBALANCE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. HIGH POTENCY APIS MARKET FOR HORMONAL IMBALANCE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. HIGH POTENCY APIS MARKET, FOR GLAUCOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. HIGH POTENCY APIS MARKET FOR GLAUCOMA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. HIGH POTENCY APIS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. HIGH POTENCY APIS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. GLOBAL HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 16. HIGH POTENCY APIS MARKET, FOR SYNTHETIC, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. HIGH POTENCY APIS MARKET FOR SYNTHETIC, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. HIGH POTENCY APIS MARKET, FOR BIOTECH, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. HIGH POTENCY APIS MARKET FOR BIOTECH, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 20. GLOBAL BIOTECH HIGH POTENCY APIS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 21. HIGH POTENCY APIS MARKET, FOR MERCHANT, BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. HIGH POTENCY APIS MARKET, FOR CAPTIVE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. HIGH POTENCY APIS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 24. NORTH AMERICA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 25. NORTH AMERICA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 26. NORTH AMERICA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA BIOTECH HIGH POTENCY APIS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA HIGH POTENCY APIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 29. U.S. HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 30. U.S. HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 31. U.S. HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 32. CANADA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 33. CANADA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 34. CANADA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 35. MEXICO HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 36. MEXICO HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 37. MEXICO HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 38. EUROPE HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 39. EUROPE HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 40. EUROPE HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 41. EUROPE BIOTECH HIGH POTENCY APIS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 42. EUROPE HIGH POTENCY APIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 43. GERMANY HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 44. GERMANY HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 45. GERMANY HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 46. FRANCE HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 47. FRANCE HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 48. FRANCE HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 49. UK HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 50. UK HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 51. UK HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 52. ITALY HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 53. ITALY HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 54. ITALY HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 55. SPAIN HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 56. SPAIN HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 57. SPAIN HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 58. REST OF EUROPE HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 59. REST OF EUROPE HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 60. REST OF EUROPE HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 61. ASIA-PACIFIC HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 62. ASIA-PACIFIC HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 63. ASIA-PACIFIC HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 64. ASIA-PACIFIC BIOTECH HIGH POTENCY APIS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC HIGH POTENCY APIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 66. JAPAN HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 67. JAPAN HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 68. JAPAN HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 69. CHINA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 70. CHINA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 71. CHINA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 72. AUSTRALIA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 73. AUSTRALIA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 74. AUSTRALIA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 75. INDIA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 76. INDIA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 77. INDIA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 78. SOUTH KOREA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 79. SOUTH KOREA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 80. SOUTH KOREA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 81. REST OF ASIA-PACIFIC HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 82. REST OF ASIA-PACIFIC HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 83. REST OF ASIA-PACIFIC HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 84. LAMEA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 85. LAMEA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 86. LAMEA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 87. LAMEA BIOTECH HIGH POTENCY APIS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 88. LAMEA HIGH POTENCY APIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 89. BRAZIL HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 90. BRAZIL HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 91. BRAZIL HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 92. SAUDI ARABIA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 93. SAUDI ARABIA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 94. SAUDI ARABIA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 95. SOUTH AFRICA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 96. SOUTH AFRICA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 97. SOUTH AFRICA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 98. REST OF LAMEA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 99. REST OF LAMEA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 100. REST OF LAMEA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
  • TABLE 101.ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 102.ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 103.ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 104.ABBVIE INC.: NET SALES,
  • TABLE 105.ABBVIE INC.: KEY STRATERGIES
  • TABLE 106.BAYER AG: COMPANY SNAPSHOT
  • TABLE 107.BAYER AG: OPERATING SEGMENTS
  • TABLE 108.BAYER AG: PRODUCT PORTFOLIO
  • TABLE 109.BAYER AG: NET SALES,
  • TABLE 110.BAYER AG: KEY STRATERGIES
  • TABLE 111.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 112.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OPERATING SEGMENTS
  • TABLE 113.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 114.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES,
  • TABLE 115.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATERGIES
  • TABLE 116.BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 117.BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
  • TABLE 118.BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 119.BRISTOL-MYERS SQUIBB COMPANY: NET SALES,
  • TABLE 120.BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
  • TABLE 121.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 122.ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 123.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 124.ELI LILLY AND COMPANY: NET SALES,
  • TABLE 125.ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 126.F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
  • TABLE 127.F. HOFFMANN-LA ROCHE: OPERATING SEGMENTS
  • TABLE 128.F. HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO
  • TABLE 129.F. HOFFMANN-LA ROCHE: NET SALES,
  • TABLE 130.F. HOFFMANN-LA ROCHE: KEY STRATERGIES
  • TABLE 131.NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
  • TABLE 132.NOVARTIS INTERNATIONAL AG: OPERATING SEGMENTS
  • TABLE 133.NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
  • TABLE 134.NOVARTIS INTERNATIONAL AG: NET SALES,
  • TABLE 135.NOVARTIS INTERNATIONAL AG: KEY STRATERGIES
  • TABLE 136.PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 137.PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 138.PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 139.PFIZER, INC.: NET SALES,
  • TABLE 140.PFIZER, INC.: KEY STRATERGIES
  • TABLE 141.SANOFI: COMPANY SNAPSHOT
  • TABLE 142.SANOFI: OPERATING SEGMENTS
  • TABLE 143.SANOFI: PRODUCT PORTFOLIO
  • TABLE 144.SANOFI: NET SALES,
  • TABLE 145.SANOFI: KEY STRATERGIES
  • TABLE 146.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 147.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 148.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 149.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
  • TABLE 150.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.HIGH POTENCY APIS MARKET SEGMENTATION
  • FIGURE 2.HIGH POTENCY APIS MARKET,2021-2031
  • FIGURE 3.HIGH POTENCY APIS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.HIGH POTENCY APIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.PATENT ANALYSIS BY COMPANY
  • FIGURE 13.PATENT ANALYSIS BY COUNTRY
  • FIGURE 14.HIGH POTENCY APIS MARKET,BY PRODUCT TYPE,2021(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF INNOVATIVE HIGH-POTENCY API HIGH POTENCY APIS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF GENERIC HIGH-POTENCY API HIGH POTENCY APIS MARKET,2021-2031(%)
  • FIGURE 17.HIGH POTENCY APIS MARKET,BY APPLICATION,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ONCOLOGY HIGH POTENCY APIS MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HORMONAL IMBALANCE HIGH POTENCY APIS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF GLAUCOMA HIGH POTENCY APIS MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS HIGH POTENCY APIS MARKET,2021-2031(%)
  • FIGURE 22.HIGH POTENCY APIS MARKET,BY TYPE OF SYNTHESIS,2021(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF SYNTHETIC HIGH POTENCY APIS MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF BIOTECH HIGH POTENCY APIS MARKET,2021-2031(%)
  • FIGURE 25.HIGH POTENCY APIS MARKET BY REGION,2021
  • FIGURE 26.U.S. HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 27.CANADA HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 28.MEXICO HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 29.GERMANY HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 30.FRANCE HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 31.UK HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 32.ITALY HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 33.SPAIN HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 34.REST OF EUROPE HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 35.JAPAN HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 36.CHINA HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 37.AUSTRALIA HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 38.INDIA HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 39.SOUTH KOREA HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 40.REST OF ASIA-PACIFIC HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 41.BRAZIL HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 42.SAUDI ARABIA HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 43.SOUTH AFRICA HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 44.REST OF LAMEA HIGH POTENCY APIS MARKET,2021-2031($MILLION)
  • FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 49.COMPETITIVE DASHBOARD
  • FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 51.ABBVIE INC..: NET SALES ,($MILLION)
  • FIGURE 52.BAYER AG.: NET SALES ,($MILLION)
  • FIGURE 53.BOEHRINGER INGELHEIM INTERNATIONAL GMBH.: NET SALES ,($MILLION)
  • FIGURE 54.BRISTOL-MYERS SQUIBB COMPANY.: NET SALES ,($MILLION)
  • FIGURE 55.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
  • FIGURE 56.F. HOFFMANN-LA ROCHE.: NET SALES ,($MILLION)
  • FIGURE 57.NOVARTIS INTERNATIONAL AG.: NET SALES ,($MILLION)
  • FIGURE 58.PFIZER, INC..: NET SALES ,($MILLION)
  • FIGURE 59.SANOFI.: NET SALES ,($MILLION)
  • FIGURE 60.TEVA PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)